Treatment of atopic dermatitis with multispecific antibodies
AssigneeNovartis AG
InventorsBo BANG, Amita BANSAL, Oliver BARENBOLD, Andrzej Marek BIENCZAK, Anton DROLLMANN, Motoi HOSOE, Michael KIFFE, Jiri KOVARIK, Anubhav Narain MATHUR, Patrycja Anna MISIOLEK, Oliver Martin POHL, Eva Christine SCHLOSSER
Life of this patent
Estimating the term…
Abstract
The invention relates to therapeutic applications of multispecific antibodies binding IL-18 and IL-13 or of antigen-binding fragments thereof in the treatment and/or prevention of atopic dermatitis or a related condition.
Claims36
-73. (canceled)
A method of treatment and/or prevention of atopic dermatitis in a human subject in need thereof, comprising administering at least one loading dose and at least one maintenance dose of a multispecific antibody or antigen-binding fragment thereof to the subject, wherein the antibody comprises:
- i) a first part that binds to IL-18 comprising:
- an HCDR1 comprising SEQ ID NO:
- 29, SEQ ID NO:
- 32, SEQ ID NO:
- 35, or SEQ ID NO:
- 38;
- an HCDR2 comprising SEQ ID NO:
- 30, SEQ ID NO:
- 33, SEQ ID NO:
- 36, or SEQ ID NO:
- 39;
- an HCDR3 comprising SEQ ID NO:
- 31, SEQ ID NO:
- 34, SEQ ID NO:
- 37, or SEQ ID NO:
- 40;
- an LCDR1 comprising SEQ ID NO:
- 1, SEQ ID NO:
- 4, SEQ ID NO:
- 7, or SEQ ID NO:
- 10;
- an LCDR2 comprising SEQ ID NO:
- 2, SEQ ID NO:
- 5, or amino acid sequence RNN, and;
- an LCDR3 comprising SEQ ID NO:
- 3, SEQ ID NO:
- 6, SEQ ID NO:
- 9, or SEQ ID NO:
- 12, and;
- ii) a second part that binds to IL-13 comprising:
- an HCDR1 comprising SEQ ID NO:
- 43, SEQ ID NO:
- 46, SEQ ID NO:
- 49, or SEQ ID NO:
- 52;
- an HCDR2 comprising SEQ ID NO:
- 44, SEQ ID NO:
- 47, SEQ ID NO:
- 50, or SEQ ID NO:
- 53;
- an HCDR3 comprising SEQ ID NO:
- 45, SEQ ID NO:
- 48, SEQ ID NO:
- 51, or SEQ ID NO:
- 54;
- an LCDR1 comprising SEQ ID NO:
- 15, SEQ ID NO:
- 18, SEQ ID NO:
- 21, or SEQ ID NO:
- 24;
- an LCDR2 comprising SEQ ID NO:
- 16, SEQ ID NO:
- 19, or amino acid sequence LAS, and;
- an LCDR3 comprising SEQ ID NO:
- 17, SEQ ID NO:
- 20, SEQ ID NO:
- 23, or SEQ ID NO:
- 26.
A method of treatment and/or prevention of atopic dermatitis in a human subject in need thereof, wherein the subject has received at least one dose of a multispecific antibody or antigen-binding fragment thereof, comprising administering at least one maintenance dose of the multispecific antibody or antigen-binding fragment thereof to the subject, wherein the antibody comprises:
- i) a first part that binds to IL-18 comprising:
- an HCDR1 comprising SEQ ID NO:
- 29, SEQ ID NO:
- 32, SEQ ID NO:
- 35, or SEQ ID NO:
- 38;
- an HCDR2 comprising SEQ ID NO:
- 30, SEQ ID NO:
- 33, SEQ ID NO:
- 36, or SEQ ID NO:
- 39;
- an HCDR3 comprising SEQ ID NO:
- 31, SEQ ID NO:
- 34, SEQ ID NO:
- 37, or SEQ ID NO:
- 40;
- an LCDR1 comprising SEQ ID NO:
- 1, SEQ ID NO:
- 4, SEQ ID NO:
- 7, or SEQ ID NO:
- 10;
- an LCDR2 comprising SEQ ID NO:
- 2, SEQ ID NO:
- 5, or amino acid sequence RNN, and;
- an LCDR3 comprising SEQ ID NO:
- 3, SEQ ID NO:
- 6, SEQ ID NO:
- 9, or SEQ ID NO:
- 12, and;
- ii) a second part that binds to IL-13 comprising:
- an HCDR1 comprising SEQ ID NO:
- 43, SEQ ID NO:
- 46, SEQ ID NO:
- 49, or SEQ ID NO:
- 52;
- an HCDR2 comprising SEQ ID NO:
- 44, SEQ ID NO:
- 47, SEQ ID NO:
- 50, or SEQ ID NO:
- 53;
- an HCDR3 comprising SEQ ID NO:
- 45, SEQ ID NO:
- 48, SEQ ID NO:
- 51, or SEQ ID NO:
- 54;
- an LCDR1 comprising SEQ ID NO:
- 15, SEQ ID NO:
- 18, SEQ ID NO:
- 21, or SEQ ID NO:
- 24;
- an LCDR2 comprising SEQ ID NO:
- 16, SEQ ID NO:
- 19, or amino acid sequence LAS, and;
- an LCDR3 comprising SEQ ID NO:
- 17, SEQ ID NO:
- 20, SEQ ID NO:
- 23, or SEQ ID NO:
- 26.
Dependencies are inferred from the claim text.